Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Chinese Journal of Experimental Traditional Medical Formulae ; (24): 88-95, 2023.
Artigo em Chinês | WPRIM | ID: wpr-976543

RESUMO

ObjectiveTo evaluate the clinical efficacy of Qimai Qinlou prescription in the treatment of elderly community-acquired pneumonia (CAP) (non-severe) with Qi and Yin deficiency and phlegm-heat obstructing lung syndrome and its impact on immune-inflammatory factors. MethodA total of 120 eligible patients were randomly divided into an observation group (60 cases) and a control group (60 cases). Both groups received intravenous cefoxitin sodium. In addition, the observation group received oral Qimai Qinlou prescription, while the control group received an oral placebo simulating Qimai Qinlou prescription. The treatment course was 14 days. The disappearance time of major clinical symptoms and signs was recorded. Traditional Chinese medicine (TCM) syndrome scores and the Clinical Research Outcome (CAP-CRO) scale scores for pneumonia of the two groups were compared. Chest computed tomography (CT) scans were performed, and peripheral blood levels of procalcitonin (PCT), interleukin-6 (IL-6), serum amyloid A (SAA), high-sensitivity C-reactive protein (hs-CRP), CD4+, CD8+, and CD4+/CD8+ were measured. The conversion rate to severe condition during hospitalization, readmission rate within 30 days after discharge, and safety evaluation were recorded. ResultAfter treatment, the observation group showed significantly shorter time of fever, cough, expectoration, and disappearance time of lung moist rales than the control group (P<0.01). The TCM syndrome scores, CAP-CRO scores in all dimensions, and total scores in both groups were significantly reduced as compared with those before treatment (P<0.01). After treatment, the observation group had a more significant reduction than the control group (P<0.01). The levels of PCT, IL-6, SAA, and hs-CRP in both groups were significantly reduced as compared with those before treatment (P<0.01). After treatment, the observation group showed a more significant reduction than the control group (P<0.01). There was no statistically significant difference in the changes of CD4+, CD8+, and CD4+/CD8+ in the control group before and after treatment. However, in the observation group, CD4+ and CD4+/CD8+ levels significantly increased (P<0.01), while CD8+ level significantly decreased (P<0.01) after treatment. After treatment, CD4+ and CD4+/CD8+ in the observation group significantly increased (P<0.01), and CD8+ significantly decreased as compared with those in the control group (P<0.01). At 7, 10, and 14 days after treatment, the curative rates in the observation group were 53.33% (32/60), 85.00% (51/60), and 91.67% (55/60), respectively, which were higher than 31.67% (19/60), 61.67% (37/60), and 68.33% (41/60) in the control group (χ2=5.763, 8.352, 10.208, P<0.05). After treatment, the total effective rate of CT scanning in the observation group was 93.33% (56/60), higher than 80.00% (48/60) in the control group (χ2=4.615, P<0.05). The conversion rate to severe condition during hospitalization in the observation group was 3.33% (2/60), lower than 15.00% (9/60) in the control group (χ2=4.904, P<0.05). The readmission rate within 30 days after discharge in the observation group was 8.33% (5/60), lower than 23.33% (14/60) in the control group (χ2=5.065, P<0.05). No serious adverse drug reactions were observed in either group during the treatment period. ConclusionQimai Qinlou prescription can enhance immune function, alleviate inflammatory reactions, significantly relieve clinical symptoms, shorten the duration of the disease, improve the curative rate and CT scanning efficacy, prevent disease progression, reduce the readmission rate in the short term, and is clinically safe for the treatment of elderly patients with non-severe CAP with Qi and Yin deficiency and phlegm-heat obstructing lung syndrome. It is worthy of further research and application.

2.
Chinese Journal of Physical Medicine and Rehabilitation ; (12): 817-820, 2015.
Artigo em Chinês | WPRIM | ID: wpr-489424

RESUMO

Objective To investigate the effects of sensory cueing (SC) on unilateral spatial neglect after stroke.Methods Five stroke survivors with unilateral spatial neglect underwent a tailored sensory cueing treatment (wearing a sensory cueing device 3 hours a day, 5 days a week for 2 weeks) in addition to their conventional rehabilitation.Two weeks before and one day before the treatment, and then one day, two weeks and 4 weeks after the treatment, all five patients were assessed using the Hong Kong edition of the behavioral inattention test (BIT-C).Results No significant changes were identified in the average BIT-C ratings at the two time point before the intervention.However, the average score had increased significantly only one day after the start of the intervention, with further significant improvement at each of the succeeding 2 week intervals.The greatest improvement was in finishing cancellation tasks, and the most severely affected patient showed the greatest improvement.Conclusion Sensory cueing treatment may be useful and feasible in reducing unilateral spatial neglect for stroke survivors.However, randomized and controlled trials with larger samples are needed to further verify its effects.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA